FDA Grants Fast Track Designation to NovaBridge's Givastomig for Metastatic Gastric Cancer
NBP is trading near its 52-week low of $1.46 (8.6% above the low).
Summary
NovaBridge Biosciences announced that its lead oncology asset, Givastomig, received FDA Fast Track Designation for first-line HER2-negative metastatic gastric cancer. This follows the 6-K filing earlier today disclosing the same event. The designation is a significant positive, as it accelerates the development and review process for the novel bispecific antibody, potentially leading to a faster path to market. Phase 1b data showed compelling efficacy and tolerability, supporting its potential as a first-in-class therapy. The company will engage in ongoing dialogue with the FDA to advance towards a registrational Phase 3 trial.
At the time of this announcement, NBP was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.6M. The 52-week trading range was $1.46 to $6.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.